Nola M. Hylton, PhD

---

Education

Massachusetts Institute of Technology (M.I.T.), B.S., 1979, Chemical Engineering
Stanford University, Ph.D., 1985, Applied Physics

---

Professional Experience

• 6/76-8/76
  Technical Associate, Bell Telephone Laboratories, Murray Hill, N.J.
• 6/77-8/77
  Research Assistant, Bell Telephone Laboratories, Murray Hill, N.J.
• 6/78-8/78
  Research Assistant, Bell Telephone Laboratories, Murray Hill, N.J.
• 9/79-12/82
  Research Assistant, E. L. Ginzton Laboratory, Stanford University, Stanford,California
• 1/83-12/84
  Research Assistant, Radiologic Imaging Laboratory, Department of Radiology, University of California, San Francisco
• 1/85-7/92
  Assistant Professor, Radiologic Imaging Laboratory, Department of Radiology, University of California, San Francisco
• 7/90-9/97
  Faculty Member, Graduate Group in Biophysics, University of California, San Francisco
• 7/92-6/95
  Assistant Professor, Magnetic Resonance Science Center, Department of Radiology, University of California, San Francisco
• 7/95-6/02
  Associate Adjunct Professor, Magnetic Resonance Science Center, Department of Radiology, University of California, San Francisco
• 9/97-present
  Faculty Member, Bioengineering Graduate Group, University of California, San Francisco and University of California, Berkeley
• 1/98-present
  Faculty Member, Breast Oncology Program, UCSF Cancer Center
• 7/02-present
  Professor in Residence, Magnetic Resonance Science Center, Department of Radiology, University of California, San Francisco
• 2/04-present
  Director, Magnetic Resonance Science Center, Dept. of Radiology, UCSF

---

Selected Publications

1. Yitta S, Joe BN, Wisner DJ, Price ER, Hylton NM. Recognizing artifacts and optimizing breast MRI at 1.5 and 3 T. AJR Am J Roentgenol. 2013 Jun; 200(6):W673-82.
   View on PubMed
2. Lehman CD, Blume JD, Demartini WB, Hylton NM, Herman B, Schnall MD. Accuracy and interpretation time of computer-aided detection among novice and experienced breast MRI readers. AJR Am J Roentgenol. 2013 Jun; 200(6):W683-9.
   View on PubMed
3. Jones EF, Sinha SP, Newitt DC, Klifa C, Kornak J, Park CC, Hylton NM. MRI Enhancement in Stromal Tissue Surrounding Breast Tumors: Association with Recurrence Free Survival following Neoadjuvant Chemotherapy. PLoS One. 2013; 8(5):e61969.
   View on PubMed
4. Wilmes LJ, McLaughlin RL, Newitt DC, Singer L, Sinha SP, Proctor E, Wisner DJ, Saritas EU, Kornak J, Shankaranarayanan A, Banerjee S, Jones EF, Joe BN, Hylton NM. High-resolution diffusion-weighted imaging for monitoring breast cancer treatment response. Acad Radiol. 2013 May; 20(5):581-9.
   View on PubMed
5. De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, Hudis CA, Hylton NM, McGuire K, Meric-Bernstam F, Meszoely IM, Nanda R, Hwang ES. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer: Translational Breast Cancer Research Consortium trial 017. Cancer. 2013 May 15; 119(10):1776-83.
   View on PubMed
6. Hall FM, Hylton N. MR Imaging for the Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy. Radiology. 2013 Jan; 266(1):367.
   View on PubMed
7. Hylton N. MR imaging for the prediction of breast cancer response to neoadjuvant chemotherapy. Radiology. 2013 Jan; 266(1):367.
   View on PubMed
8. Hylton NM, Blume JD, Bernreuter WK, Pisano ED, Rosen MA, Morris EA, Weatherall PT, Lehman CD, Newstead GM, Polin S, Marques HS, Esserman LJ, Schnall MD. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. Radiology. 2012 Jun; 263(3):663-72.
   View on PubMed
9. Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart M. A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. Lancet Oncol. 2012 Jun; 13(6):e240-8.
   View on PubMed
10. Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012 Sep 10; 30(26):3242-9.
    View on PubMed
11. Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012 Apr; 132(3):1049-62.
    View on PubMed
12. Singer L, Wilmes LJ, Saritas EU, Shankaranarayanan A, Proctor E, Wisner DJ, Chang B, Joe BN, Nishimura DG, Hylton NM. High-resolution Diffusion-weighted Magnetic Resonance Imaging in Patients with Locally Advanced Breast Cancer. Acad Radiol. 2012 May; 19(5):526-34.
    View on PubMed
13. Partridge SC, Singer L, Sun R, Wilmes LJ, Klifa CS, Lehman CD, Hylton NM. Diffusion-weighted MRI: influence of intravoxel fat signal and breast density on breast tumor conspicuity and apparent diffusion coefficient measurements. Magn Reson Imaging. 2011 Nov; 29(9):1215-21.
    View on PubMed
14. Meyerson AF, Lessing JN, Itakura K, Hylton NM, Wolverton DE, Joe BN, Esserman LJ, Hwang ES. Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ. Breast. 2011 Dec; 20(6):529-33.
    View on PubMed
15. McLaughlin R, Hylton N. MRI in breast cancer therapy monitoring. NMR Biomed. 2011 Jul; 24(6):712-20.
    View on PubMed
16. Liu S, Shah SJ, Wilmes LJ, Feiner J, Kodibagkar VD, Wendland MF, Mason RP, Hylton N, Hopf HW, Rollins MD. Quantitative tissue oxygen measurement in multiple organs using 19F MRI in a rat model. Magn Reson Med. 2011 Dec; 66(6):1722-30.
    View on PubMed
17. Klifa C, Suzuki S, Aliu S, Singer L, Wilmes L, Newitt D, Joe B, Hylton N. Quantification of background enhancement in breast magnetic resonance imaging. J Magn Reson Imaging. 2011 May; 33(5):1229-34.
    View on PubMed
18. Peng C, Chang CB, Tso HH, Flowers CI, Hylton NM, Joe BN. MRI appearance of tumor recurrence in myocutaneous flap reconstruction after mastectomy. AJR Am J Roentgenol. 2011 Apr; 196(4):W471-5.
    View on PubMed
19. Arasu VA, Chen RC, Newitt DN, Chang CB, Tso H, Hylton NM, Joe BN. Can signal enhancement ratio (SER) reduce the number of recommended biopsies without affecting cancer yield in occult MRI-detected lesions? Acad Radiol. 2011 Jun; 18(6):716-21.
    View on PubMed
20. Nabavizadeh N, Klifa C, Newitt D, Lu Y, Chen YY, Hsu H, Fisher C, Tokayasu T, Olshen AB, Spellman P, Gray JW, Hylton N, Park CC. Topographic enhancement mapping of the cancer-associated breast stroma using breast MRI. Integr Biol (Camb). 2011 Apr; 3(4):490-6.
    View on PubMed

View on UCSF Profiles